Endoscopy Sleeve Gastroplasty for Insulin Resistance and Obesity

Recruiting in Palo Alto (17 mi)

Overseen ByElena Anna O. De Filippis, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils (EOS), and adipose tissue (AT) in human health and in disease states such as obesity and insulin resistance.

Eligibility Criteria

This trial is for adults with obesity (BMI>30 kg/m2) who are mostly sedentary, have insulin resistance (hemoglobin A1c > 5.7%), and plan to undergo endoscopic gastroplasty at Mayo Clinic Arizona. Participants should not have had significant weight changes in the past 6 months, be non-smokers, and not on medications affecting glucose or lipid metabolism.

Inclusion Criteria

You have a body mass index (BMI) higher than 30, which means you are very overweight.

You may be a candidate for an endoscopic gastroplasty at Mayo Clinic Arizona

Your body weight has not changed by more than 5% in the past 6 months.

+15 more

Exclusion Criteria

You have a history of chronic lung disease or allergic conditions.

You are currently taking corticosteroid medication.

You have had certain autoimmune diseases such as ulcerative colitis, Crohn's disease, or rheumatoid arthritis.

+7 more

Participant Groups

The study aims to understand how eosinophils interact with adipose tissue in conditions like obesity and insulin resistance by observing patients undergoing endoscopy sleeve gastroplasty—a procedure that reduces stomach size to aid weight loss.

1Treatment groups

Experimental Treatment

Group I: Subjects with ObesityExperimental Treatment1 Intervention

Subjects will be recruited to undergo endoscopic sleeve gastroplasty. The subjects will be studied at baseline, 30, 60, 90 days after procedure